EUCTR2006-003398-28-BG进行中（未招募）不适用
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis - PURSUIT Subcutaneous
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Centocor BV
- 入组人数
- 1,002
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Are men or women 18 years of age or older.
- •2.Had UC diagnosed prior to screening.
- •3. Prior or current medication for UC must include at least 1 of the following:
- •Current treatment with OR
- •History to respond to at least 1 of the following therapies: oral 5-ASAs, oral corticosteroids, 6-MP, or AZA OR
- •have or have had history of corticosteroid dependency.
- •4. Prior to the screening endoscopy or the earliest entry in the Mayo diary card that
- •will be used to calculate the baseline Mayo score, whichever of these 2 events comes first, several conditions must be met. See page 20 and 21 of the protocol.
- •5. Must be ambulatory and have moderately to severely active UC confirmed during
- •the screening sigmoidoscopy by a = 2 endoscopy subscore of the Mayo score.
- •6. Must have results from a biopsy collected at the screening endoscopy procedure or have a previous biopsy result obtained within the last year that is consistent with the diagnosis of UC.
- •7.Have moderately to severely active UC, defined as a baseline (Week 0) Mayo score of 6 to 12, inclusive.
- •8.All subjects = 45 years of age, must either have had a colonoscopy to assess for the presence of adenomatous polyps within 5 years of the first administration of study agent or a colonoscopy to assess for the presence of adenomatous polyps at the screening visit. The adenomatous polyps must be removed prior to the first administration of study agent.
- •9.All subjects who have had extensive colitis for = 8 years, or disease limited to the left side of the colon for =10 years, must either have had a colonoscopy to assess the presence of dysplasia within 1 year prior to the first administration of study agent or a colonoscopy to assess the presence of malignancy at the screening visit.
- •10.The investigator has discussed with the subject the information contained within the informed consent regarding anti-TNF therapies and the potential risk of cancer, and has reviewed with the subject country-specific guidance (local practice) on cancer screening and the impact of life-style choices (eg, smoking) on the risk of developing cancer.
- •11.Are considered eligible according to the specific TB screening criteria. See page 22 of the protocol.
- •12.Have negative stool results for enteric pathogens.
- •13.During the study and for 6 months after receiving the last administration of study agent, women of childbearing potential or men capable of fathering children must agree to use adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilization). Women of childbearing potential must test negative for pregnancy at screening and at Week 0.
- •14.Have screening detailed laboratory test results. See page 22 of the protocol.
- •15.Must be able and willing to adhere to the study visit schedule and comply with other protocol requirements.
- •16.Are capable of providing informed consent, which must be obtained prior to any study-related procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Have severe extensive colitis, as defined in protocol.
- •2.Have UC limited to the rectum only or to < 20 cm of the colon.
- •3.Presence of a stoma.
- •4.Presence or history of a fistula.
- •5.Require, or required within the 2 months prior to screening, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage, or other conditions possibly confounding the evaluation of benefit from study agent treatment.
- •6.Presence of symptomatic colonic or small bowel obstruction, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy).
- •7.History of extensive colonic resection (eg, less than 30 cm of colon remaining) that would prevent adequate evaluation of the effect of study agent on clinical disease activity.
- •8.History of colonic mucosal dysplasia.
- •9.Presence on screening endoscopy of adenomatous colonic polyps, if not removed prior to study entry, or history of adenomatous colonic polyps that were not removed.
- •Concomitant or previous medical therapies received:
- •10.Have ever received biologic therapy targeted at TNFa,
- •11. Have received natalizumab within 12 months of first study agent administration.
- •12. Have received agents that deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab) within 12 months of first study agent administration, or continue to manifest depletion of B or T cells more than 12 months after completion of therapy with lymphocyte-depleting agents.
- •13.Are receiving oral corticosteroids at a dose of greater than 40 mg of prednisone or its equivalent per day.
- •14.Have received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 8 weeks prior to first administration of study agent.
- •15.Have a known hypersensitivity to human immunoglobulin proteins or other components of golimumab.
- •16.Have used any investigational drug within 4 weeks prior to first administration of study agent or within 5 half lives of the investigational agent, whichever is longer.
- •17.Have used apheresis (ie, Adacolumn apheresis) within 2 weeks prior to first administration of study agent.
- •Infections or predisposition to infections:
- •18.Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening.
- •19.Have a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (eg, bronchiectasis), sinusitis, recurrent urinary tract infection (eg, recurrent pyelonephritis, chronic cystitis), an open, draining, or infected skin wound, or an ulcer.
- •20.Have immune deficiency syndrome (eg, severe combined immunodeficiency syndrome [SCIDS], T cell deficiency syndromes, B cell deficiency syndromes, and chronic granulomatous disease).
- •21. Are known to be infected with HIV, hepatitis B, or hepatitis C.
- •22.Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening.
- •23.Have had a nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months prior to screening.
- •24.Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or curre
研究者
相似试验
进行中（未招募）
不适用
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis - PURSUIT SubcutaneousEUCTR2006-003398-28-LTCentocor BV676
进行中（未招募）
不适用
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to Severely Active Ulcerative Colitislcerative Colitis (UC)MedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2006-003397-94-ATCentocor BV676
进行中（未招募）
不适用
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to Severely Active Ulcerative Colitislcerative Colitis (UC)MedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2006-003397-94-NLCentocor BV676
进行中（未招募）
不适用
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitislcerative Colitis (UC)MedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2006-003398-28-LVCentocor BV676
未知
2 期
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative ColitisJPRN-jRCT2080220712JANSSEN PHARMACEUTICAL K.K